Table 27Summary of studies on posterior subcapsular cataracts

NDesignPopulationResultsQuality rating
Chylack et al. 20082571,568RCTAdults (age ≥ 18)Mean changes in nuclear opalescence and cortical and posterior subcapsular opacification were small and similar between groupsFair
Childhood Asthma Management Program Research Group, 2000255, 2561041RCTChildrenNo significant differences in PSC between BUD-, nedocromil-, or placebo-treated childrenGood
Agertoft et al., 1998263268Prospective cohortChildren (age 5–16)No significant differences in PSC between BUD-treated children and matched controlsFair
Cumming et al. 19972643654Cross-sectionalAdults (age 49–97)Increased risk of nuclear and PSC among ICS usersNA
Garbe et al. 199826525,545Case-controlRAMQ age ≥ 70 yearsIncreased risk of cataract extraction for ICS users only at high dose and durationGood
Jick et al. 2001266201,816 (3,581)Cohort + case-controlGPRD (age 3–90)Dose-, duration-, and age-related increased risk of cataracts among ICS users; no increase in risk for age < 40Good
Smeeth et al. 200326730,958Case-controlGPRD age ≥ 40 yearsDose- and duration-related increased risk of cataracts among ICS usersFair

Abbreviations: BUD = Budesonide; GPRD= general practice research database; ICS = Inhaled Corticosteroids; RCT= randomized controlled trial; PSC= posterior subcapsular cataracts; RAMQ= regi de l’assurance maladie du Quebec database

No difference = no statistically significant difference or tests of statistical significance were not reported and outcomes are similar.

From: Results

Cover of Drug Class Review: Controller Medications for Asthma
Drug Class Review: Controller Medications for Asthma: Final Update 1 Report [Internet].
Jonas DE, Wines RCM, DelMonte M, et al.
Portland (OR): Oregon Health & Science University; 2011 Apr.
Copyright © 2011 by Oregon Health & Science University.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.